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Chronic	kidney	disease	(CKD)	is	a	major	public	health	concern	with	rising	
prevalence.	Vitamin	D	deficiency	(<20	ng/mL)	and	insufficiency	(20–29	ng/mL)	are	
common	among	patients	with	CKD	undergoing	dialysis.	The	objective	was	to	
review	current	research	on	vitamin	D	supplementation	for	dialysis	patients	and	
the	effect	on	their	serum	vitamin	D	levels.	
There	are	two	main	forms	of	vitamin	D	found	in	foods,	cholecalciferol	and	
ergocalciferol.		Cholecalciferol	(vitamin	D3)	is	taken	in	the	diet	from	fortified	dairy	
products	and	fish	oils	or	is	synthesized	in	the	skin.1 The	largest	quantities	of	the	
vitamin	in	food	are	found	in	fatty	fish	like	swordfish,	salmon,	tuna,	and	sardines.1-2
The	fortified	foods	include	milk,	yogurt,	cheese,	orange	juice,	breads	and	cereals.1-
2
A	major	source	of	vitamin	D	is	what	is	made	in	the	body	from	the	steroid	5,7-
cholestradienol,	commonly	called	7-dehydrocholesterol.2-3 This	steroid	is	derived	
from	cholesterol.2
The	biologically	active	form	of	Vitamin	D,	1,25(OH)2D3,	affects	calcium	and	
phosphorus	homeostasis	and	has	numerous	other	diverse	physiological	
functions.1 The	active	form	of	vitamin	D	is	also	called	calcitriol.1
The	population	studied	were	patients,	ages	18	years	old	and	up,	with	end-
stage	renal	disease	undergoing	dialysis.		The	sample	size	was	70	patients	
with	an	effect	size	of	0.8.	A	similar	study	was	used	to	determine	sample	
size.4 The	G*power	calculation	was	completed	by	using	the	mean	vitamin	D	
levels	from	a	similar	study.	
Participants	(n=70)	diagnosed	with	end-stage	renal	disease	and	
undergoing	dialysis	were	assigned	to	groups	that	received	either	50,000	
IU	cholecalciferol	per	week	if	the	patient	was	deficient	(<20	ng/mL)	or	
10,000	IU	cholecalciferol	per	day	if	the	patient	was	insufficient	(20-30	
ng/mL).	The	serum	circulating	25-hydroxyvitamin	D	[25(OH)D]	level	was	
monitored	once	per	month	to	assess	how	long	vitamin	D	
supplementation	is	needed	to	obtain	normal	serum	vitamin	D	levels	
(>30ng/mL).		
After	3	months,	the	serum	25(OH)D	increased	from	14.3	± 4.7	ng/mL	to	
43.1	± 11.0	ng/mL	(p	<	0.05)	in	the	50,000	IU	cholecalciferol	per	week	
group	(n=30).	The	10,000	IU	per	cholecalciferol	per	day	group	(n=40)	
increased	in	serum	25(OH)D	from	23.9	± 4.2	ng/mL	to	33.5	± 4.3	ng/mL	
(p<0.05).	Results	were	statistically	significant	with	p<0.05.	
Further	research	is	needed	for	the	specific	timeframe	that	vitamin	D3
supplementation	is	beneficial	for	dialysis	patients	once	normal	serum	
levels	are	achieved	to	maintain	normal	levels.	Also,	more	research	is	
needed	to	determine	adequate	supplementation	timeframe	when	
patients	are	taking	supplements	and	increasing	dietary	vitamin	D	intake	
and	sunshine	exposure.	
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